Nivalis Therapeutics, Inc. (NASDAQ:ALPN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday.

According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “

ALPN has been the topic of a number of other reports. ValuEngine raised shares of Nivalis Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 27th. Ladenburg Thalmann Financial Services started coverage on shares of Nivalis Therapeutics in a research report on Thursday, July 27th. They set a “buy” rating and a $17.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $5.75.

Nivalis Therapeutics (ALPN) traded down $0.14 during trading hours on Wednesday, reaching $10.01. 97,100 shares of the company were exchanged, compared to its average volume of 57,511. Nivalis Therapeutics has a 1-year low of $7.20 and a 1-year high of $26.48.

ILLEGAL ACTIVITY WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/11/15/nivalis-therapeutics-inc-alpn-stock-rating-upgraded-by-zacks-investment-research.html.

An institutional investor recently bought a new position in Nivalis Therapeutics stock. Sowell Financial Services LLC acquired a new position in shares of Nivalis Therapeutics, Inc. (NASDAQ:ALPN) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 15,714 shares of the biotechnology company’s stock, valued at approximately $162,000. Sowell Financial Services LLC owned approximately 0.40% of Nivalis Therapeutics as of its most recent SEC filing.

Nivalis Therapeutics Company Profile

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

Get a free copy of the Zacks research report on Nivalis Therapeutics (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Nivalis Therapeutics (NASDAQ:ALPN)

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.